Vericel Corporation (VCEL) Expected to Post Earnings of -$0.17 Per Share
Equities research analysts expect that Vericel Corporation (NASDAQ:VCEL) will announce earnings per share (EPS) of ($0.17) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Vericel Corporation’s earnings. Vericel Corporation posted earnings of ($0.38) per share during the same quarter last year, which suggests a positive year over year growth rate of 55.3%. The firm is expected to announce its next earnings results on Monday, November 6th.
According to Zacks, analysts expect that Vericel Corporation will report full year earnings of ($0.65) per share for the current financial year, with EPS estimates ranging from ($0.67) to ($0.62). For the next financial year, analysts expect that the business will report earnings of ($0.39) per share, with EPS estimates ranging from ($0.54) to ($0.23). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Vericel Corporation.
Vericel Corporation (NASDAQ:VCEL) last announced its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.16. The firm had revenue of $16.95 million for the quarter.
Several equities research analysts have weighed in on the stock. BTIG Research set a $6.00 target price on shares of Vericel Corporation and gave the stock a “buy” rating in a report on Monday, October 2nd. Piper Jaffray Companies reiterated a “buy” rating and issued a $7.00 target price on shares of Vericel Corporation in a report on Thursday, August 10th.
Shares of Vericel Corporation (NASDAQ VCEL) traded down 7.55% during mid-day trading on Thursday, reaching $4.90. 1,510,075 shares of the company’s stock traded hands. Vericel Corporation has a 52 week low of $2.00 and a 52 week high of $6.30. The firm’s market cap is $160.84 million. The company’s 50 day moving average is $4.58 and its 200-day moving average is $3.34.
Large investors have recently modified their holdings of the stock. First Washington CORP acquired a new stake in shares of Vericel Corporation during the second quarter worth $2,230,000. Archon Capital Management LLC acquired a new stake in shares of Vericel Corporation during the second quarter worth $4,412,000. Perkins Capital Management Inc. raised its holdings in shares of Vericel Corporation by 12.6% during the second quarter. Perkins Capital Management Inc. now owns 257,600 shares of the biotechnology company’s stock worth $850,000 after acquiring an additional 28,850 shares during the period. Stonepine Capital Management LLC raised its holdings in shares of Vericel Corporation by 73.3% during the first quarter. Stonepine Capital Management LLC now owns 3,265,323 shares of the biotechnology company’s stock worth $9,143,000 after acquiring an additional 1,381,523 shares during the period. Finally, Vanguard Group Inc. raised its holdings in shares of Vericel Corporation by 7.9% during the second quarter. Vanguard Group Inc. now owns 1,212,799 shares of the biotechnology company’s stock worth $4,002,000 after acquiring an additional 88,645 shares during the period. Institutional investors and hedge funds own 33.84% of the company’s stock.
WARNING: “Vericel Corporation (VCEL) Expected to Post Earnings of -$0.17 Per Share” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/10/08/vericel-corporation-vcel-expected-to-post-earnings-of-0-17-per-share.html.
Vericel Corporation Company Profile
Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Vericel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel Corporation and related stocks with our FREE daily email newsletter.